National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
Send to Printer
Carcinoma of Unknown Primary Treatment (PDQ®)     
Last Modified: 07/25/2008
Health Professional Version
Recurrent Carcinoma of Unknown Primary

Current Clinical Trials

The prognosis for any treated cancer patient with progressing, recurring, or relapsing disease is poor, regardless of cell type or stage. Deciding on further treatment depends on many factors, including the specific cancer, prior treatment, and site of recurrence, as well as individual patient considerations. Treatments that are under clinical evaluation are appropriate and should be considered when possible.

Current Clinical Trials

Check for U.S. clinical trials from NCI's PDQ Cancer Clinical Trials Registry that are now accepting patients with recurrent carcinoma of unknown primary 1. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.

General information about clinical trials is also available from the NCI Web site 2.



Table of Links

1http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?diagnosis=41133&tt=1&a
mp;format=2&cn=1
2http://www.cancer.gov/clinicaltrials